Join collection
Hello, welcome to our official website!
互联网保险监管升级 中小险企盼跨区销售险种扩容
2019-01-12

  近日,银保监会下发了《关于继续加强互联网保险监管有关事项的通知》。银保监会表示,正在加快《互联网保险业务监管暂行办法》(以下简称《暂行办法》)的修订工作,在新的规定出台以前,原《暂行办法》继续有效.据悉,《暂行办法》于2015年10月1日起施行,施行期限为3年。

  3年来,随着互联网金融迅猛发展,互联网保险业务也呈现加速发展态势。而随着互联网保险驱动方发生根本变化,保险公司向平台所有者转变,一些新的风险趋势有所冒头,对现有的监管制度提出了挑战。此前,银保监会允许意外险、定期寿险等保险业务可以扩展至未设分公司的省、自治区和直辖市。而此次修订《暂行办法》是否放开更多险种,如重疾险跨区销售成为险企关注的一个焦点。

  互联网保险格局生变,中国互联网保险起步很早,引爆市场的一个标志性事件是,2012年12月国华人寿通过淘宝聚划算平台借助万能险产品创造了三天一亿元的销售神话。2013年国内首家互联网保险公司众安在线财产保险获得原保监会批准成立,此后中国互联网保险进入高速发展阶段,互联网保险的保费几乎每年上一个台阶。2015年以来,随着互联网保险驱动方发生根本变化,一些新的问题和风险趋势有所冒头,对现有的监管制度和监管环境提出了挑战。

  如第三方网络平台数量巨大,新媒体、新技术参与程度较高,对保险业务手续费、经营流程、资金收付等进行深度掌控,通过与保险公司的业务合作,间接受保险监管部门监管,不受保险监管部门直接或实质性监管。这导致保险监管规定的信息披露要求、资金收付要求、手续费支付要求等往往在业务实践中难以得到有效的贯彻落实,带来较大的合规风险。

  某些在线平台暗藏“搭售”,通过默认勾选的方式销售一些保险产品,未明确列明承保主体或代理销售主体,未完整披露保险产品条款等相关重要信息,侵害了消费者的知情权、自主选择权等。

  中小保险公司在目前互联网保险环境下亦生存艰难。从目前的格局来看,保费仍然明显向大公司集中。据中保协的数据,2018年上半年,保费规模*大的8家保险公司累计实现互联网财险保费收入235.70亿元,占该市场的份额为72.21%。

  “中小公司互联网保险业务批下来也没法活,在现在这个环境,只要一做业务就亏。前三大保险公司占62%的互联网保险份额,*后39家小的保险公司在保费环节每家不足10亿元,这个数字触目惊心。”某中小保险公司高管感叹。

  同时,互联网保险的内涵与外延发生了很多变化,由作为渠道或场景销售保险为主逐渐过渡到保险科技赋能保险的内涵。而《暂行办法》很大程度上还是沿用*早的互联网保险定义,以通过互联网渠道销售保险产品为主来衡量和评定,需要结合新形势和环境进行修改,提升监管的适应性。

  记者获悉,近日银保监会下发《关于继续加强互联网保险监管有关事项的通知》,其重申2015年原保监会发布《暂行办法》以来,互联网保险业务持续健康发展,服务能力不断增强。银保监会表示,正在加快《暂行办法》的修订工作,在新的规定出台以前,《暂行办法》继续有效。

  一位不愿具名的保险监管人士表示,既要提升监管的适应性,也要保持监管的稳定性。对互联网保险监管采取相对开放的态度,对于互联网保险作业模式与原有监管规则之间的冲突,不能简单从合规的层面予以否定,应该从更深层面查找规则的逻辑基础,以风险防范为*终目的,寻求规则适应与鼓励创新之间的平衡。

“原有监管规则被打破以后,新的规则要及时跟上,对监管来说,守住风险底线是硬道理。”该保险监管人士说。

  跨区销售险种引关注

  银保监会在文件中表示,其正在积极推进互联网保险监管的各项工作,要求各保险机构要切实加强产品创新能力、风险管控能力、客户服务能力建设,要求保险机构认真落实互联网保险业务经营区域和信息披露有关要求,强化保险消费者保护,确保互联网保险业务合规经营。

  在《暂行办法》中,原保监会允许保险代理公司和保险经纪公司在具备销售互联网保险的条件和完成互联网保险备案之后,即可以借助互联网销售保险产品。保险公司也可以自建互联网渠道和借助完成互联网备案的互联网平台销售保险。

  特别是原保监会在《暂行办法》中提出:“保险公司在具有相应内控管理能力且能满足客户服务需求的情况下,可将下列险种的互联网保险业务经营区域扩展至未设立分公司的省、自治区、直辖市:(一)人身意外伤害保险、定期寿险和普通型终身寿险;(二)投保人或被保险人为个人的家庭财产保险、责任保险、信用保险和保证保险;(三)能够独立、完整地通过互联网实现销售、承保和理赔全流程服务的财产保险业务;(四)中国保监会规定的其他险种”。

  目前,市场上有超过100家保险公司开展了互联网保险业务,特别是中小保险公司希望借助互联网渠道实现跨越式发展,所以中小保险公司希望银保监会放开更多的险种跨区销售。

  有知情人士透露,此前银保监会对互联网保险监管办法征求意见。不过,目前并未见银保监会公开发布新的互联网保险监管办法征求意见稿。事实上,记者在采访中了解到,中小寿险公司希望放开重疾险、分红险、年金险、万能险和投连险等产品全国销售。而中小财险公司则希望放开重疾险(包括百万医疗之类的健康险产品)、车险等产品全国销售。

  有小型保险公司人士认为,可以放开重疾险(包括百万医疗产品)、年金险、车险等更多产品跨区销售,像重疾险、年金险这类产品其实理赔服务不多,而且第三方服务公司很多,保险公司完全可以交给第三方服务公司来做;而车险跨区销售,此前众安保险、泰康在线已经进行了尝试,也并未引起市场本质的变化,而且中保车服也已经成立,完全可以进行更多范围的尝试。

  不过,大型保险公司却并不这么认为,特别是重疾险、车险这类产品属于重服务的产品,放开中小保险公司跨区销售反而会影响保险服务,因为中小保险公司的服务能力跟不上。业内有观点认为,分支机构的数量一定程度上会影响将来健康险理赔便利性,一般开设在非消费者所在地的分支机构对消费者的价值有限,除非该用户未来会移居到该地区生活工作。来源:圈中人


暂无评论!
我要评论 只有购买过该商品的用户才能评论。

Major Chinese biopharmaceutical company Hansoh Pharmaceutical Group Company Limited (Hanmori Pharmaceutical Group Co., Ltd., Hanso Pharmaceutical) and AI ) Atomwise, Inc., a leader in the field, announced the collaboration. The purpose of the collaboration is to design and discover potential drug candidates for a total of 11 private target proteins in multiple therapeutic areas.Atomwise and Hansoh Pharma scientific teams work closely together in each program. The combination of complementary expertise and technology has the potential to dramatically increase success rates and shorten schedules in drug discovery and clinical development.Dr. Aifeng Lyu, President of Jiangsu Hansoh Pharmaceutical Group Co., Ltd., a subsidiary of Hansoh Pharma, said: “Atomwise is the best partner for Hansoh Pharma to use AI technology to innovate and create diverse small molecule pipelines in oncology and other therapeutic areas. I am very impressed with the team and I believe that working together will provide a special opportunity to develop first-in-class and best-in-class therapeutics. "Dr. Abraham Heifets, CEO of Atomwise, said: “It is a great pleasure for us to partner with Chinese biopharmaceutical giant Hansoh Pharma. Hansoh Pharma shares our strong commitment to innovation and our mission to influence patient health globally.”Atomwise's world-class AI platform for structure-based drug design leads the way in finding hit compounds, selecting lead compounds from hit compounds, and optimizing lead compounds. Hansoh Pharma will contribute in its capacity in biological assays and medicinal chemistry, and will lead the subsequent preclinical and clinical development.Subject to the terms of the collaboration, Atomwise will receive revenue based on private technology fees, option exercise fees, royalties, and sublicenses and sales of assets created under the collaboration. Based on historical average sales of small molecule drugs, the overall potential value of this transaction for Atomwise may exceed the potential value of a hit drug if all projects succeed. Hansoh Pharma receives development and commercialization rights in all fields and regions.2019 Asia-pacific pharma IP Leader Summit: http://en.zenseegroup.com/p/404716/ will be held in Beijing  on November 14-15, and will attract more than 500 industry experts from domestic and foreign pharmaceutical companies, biotechnology companies, governments, associations, law firms, intellectual property agents and other companies to attend.Official registration and consultation channels:Contact:AnnPhone: 021-65650305Email:Marketing@zenseegroup.comhttp://www.zenseegroup.com/forms/view/22113/

Akari Therapeutics, Plc, a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement (C5) and/or leukotriene (LTB4) systems are implicated, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for nomacopan for the treatment of bullous pemphigoid (BP).“BP, a severe blistering skin condition with no approved treatments, is an exciting therapeutic target for our lead drug candidate, nomacopan. It is also a disease of increasing prevalence due to an aging population and improving diagnosis,” said Clive Richardson, Chief Executive Officer of Akari Therapeutics. “Orphan drug designation for nomacopan is a major step forward for the program, positioning nomacopan for eligibility for an additional seven years of marketing exclusivity in BP if nomacopan is approved by the FDA. This news is in addition to the recent orphan drug designation received for our HSCT-TMA program.”The Company plans to release new safety and efficacy data from an ongoing Phase II trial with nomacopan in patients with BP at an oral presentation by Dr. Christian Sadik at the 28th European Academy of Dermatology and Venereology (EADV) Congress on October 10, 2019. In August, the Company announced new data demonstrating the synergistic benefits of nomacopan’s dual C5 and LTB4 inhibitory activity in pemphigoid disease, generated by Dr. Christian Sadik’s group at University of Lubeck, Germany, and published in the August 2019 edition of JCI Insight [link].Orphan drug designation by the FDA is granted to promote the development of drugs that target conditions affecting 200,000 or fewer U.S. patients annually and that are expected to provide significant therapeutic advantage over existing treatments. Orphan designation qualifies Akari for various benefits, including seven years of market exclusivity following marketing approval, tax credits on U.S. clinical trials, eligibility for orphan drug grants, and a waiver of certain administrative fees.2019 Asia-pacific pharma IP Leader Summit: http://en.zenseegroup.com/p/404716/ will be held in Beijing  on November 14-15, and will attract more than 500 industry experts from domestic and foreign pharmaceutical companies, biotechnology companies, governments, associations, law firms, intellectual property agents and other companies to attend.Official registration and consultation channels:Contact:AnnPhone: 021-65650305Email:Marketing@zenseegroup.comhttp://www.zenseegroup.com/forms/view/22113/

China's leading biopharmaceutical company Hansoh Pharmaceutical Group Company Limited (" Hansen Pharmaceutical ") and drug discovery artificial intelligence (AI) Atomwise, Inc. (" Atomwise ") , a leader in the field, announced a collaborative design and discovery of potential drug candidates for up to 11 unexposed target proteins in a variety of therapeutic areas.Atomwise and Hansen Pharmaceutical's scientific team will work closely together in these projects. The combination of complementary expertise and technology is expected to significantly increase success and reduce timelines for drug discovery and clinical development.Dr. Lu Aifeng, President of Jiangsu Hansoh Pharmaceutical Group Co., Ltd., said: Hansen Pharmaceutical is committed to using AI technology to innovate and develop diverse small molecules in the field of cancer and other therapeutics. Atomwise is the right partner for Hansen Pharmaceuticals. We are very impressed with Atomwise's AI platform, capabilities and team. We believe that the two companies will have an excellent opportunity to develop similar and best-in-class therapeutic drugs. ."Dr. Abraham Heifets, CEO of Atomwise, said: "We are very excited to work with Hansen Pharmaceutical, China's leading biopharmaceutical company. Hansen Pharmaceuticals and we all have strong commitment to innovation and a common mission to influence the health of patients worldwide. ."The world-class AI platform for Atomwise structured drug design will guide efforts in hit discovery, accidental discovery to hit-to-lead selection, and optimization of lead compounds. Hansen Pharmaceuticals is committed to biological testing and pharmaceutical chemistry, as well as leading subsequent preclinical and clinical development activities.Under the terms of the partnership, Atomwise will receive undisclosed technology royalties, optional royalties, royalties, and subcontracting authorizations or revenue generated from the sale of the derivative assets. Based on the historical average turnover of small molecule drugs, the potential total value of all successful projects with Atomwise's transaction may exceed potential selling drugs. Hanson Pharmaceuticals will receive development and commercialization rights in all fields and geographies.2019 Asia-pacific pharma IP Leader Summit: http://en.zenseegroup.com/p/404716/ will be held in Beijing  on November 14-15, and will attract more than 500 industry experts from domestic and foreign pharmaceutical companies, biotechnology companies, governments, associations, law firms, intellectual property agents and other companies to attend.Official registration and consultation channels:Contact:AnnPhone: 021-65650305Email:Marketing@zenseegroup.comhttp://www.zenseegroup.com/forms/view/22113/

WEDNESDAY, SEPTEMBER 11, 2019I-Mab Biopharma (I-Mab), a China and U.S.-based clinical stage biopharmaceutical company exclusively focused on the discovery and development of potential first-in-class and best-in-class biologics in immuno-oncology and autoimmune diseases announces the signing of a collaboration agreement with Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences), an innovation-driven biopharmaceutical company to evaluate the combination therapy of I-Mab's TJD5, a proprietary innovative CD73 antibody with Junshi Biosciences' Toripalimab (Trade name: Tuoyi), a recombinant humanized anti-PD-1 monoclonal antibody in patients with cancers in China.Dr. Jingwu Zang, Founder and Chairman of I-Mab, commented, "TJD5 is an innovative CD73 antibody with best-in-class potential that has entered into Phase I trial in the US. We are very pleased to collaborate with Junshi to explore the clinical synergies with Toripalimab which is an innovative drug with distinctive treatment advantages. We are looking forward to bringing more clinical benefits to patients across various cancer types."Dr. Ning Li, CEO of Junshi Biosciences, commented, "As an anti multi-tumor drug, toripalimab has shown good safety and efficacy in clinical trials with mono and combination therapy. We believe, through the cooperation with I-Mab, we could continue to explore the combination potential of toripalimab and innovative drugs to improve the outcomes of immune-oncology therapy, lightening hope for more patients.2019 Asia-pacific pharma IP Leader Summit: http://en.zenseegroup.com/p/404716/ will be held in Beijing  on November 14-15, and will attract more than 500 industry experts from domestic and foreign pharmaceutical companies, biotechnology companies, governments, associations, law firms, intellectual property agents and other companies to attend.Official registration and consultation channels:Contact:AnnPhone: 021-65650305Email:Marketing@zenseegroup.comhttp://www.zenseegroup.com/forms/view/22113/

TUESDAY, SEPTEMBER 10, 2019ProBioGen AG, a premier service and technology provider for complex therapeutic antibodies and glycoproteins, today announced the closing of a license agreement with Bayer AG for the  GlymaxX® Technology. Under the terms of the agreement, Bayer will leverage the technology to further increase the potency of an undisclosed antibody candidate for oncological indications.ProBioGen’s proven antibody-dependent cellular cytotoxicity (ADCC) enhancing technology GlymaxX® will be applied during cell line development.“We are glad to add Bayer to our list of licensees”, says ProBioGen’s Chief Executive Officer Dr. Wieland Wolf. “The GlymaxX® technology is clinically proven and is a very flexible technology which is liked by all cell lines.”About ProBioGen AGProBioGen is a premier, Berlin-based specialist for developing and manufacturing complex therapeutic antibodies and glycoproteins. Combining both state-of-the-art development services, based on ProBioGen’s CHO.RiGHT™ expression and manufacturing platform, together with intelligent product-specific technologies yields biologics with optimized properties.Rapid and integrated cell line and process development, comprehensive analytical development and following reliable GMP manufacturing is performed by a highly skilled and experienced team.All services and technologies are embedded in a total quality management system to assure compliance with international ISO and GMP standards (EMA/FDA).ProBioGen was founded 1994, is privately owned, and located in Berlin, Germany.About GlymaxX®The GlymaxX® technology, developed by ProBioGen, prevents the cellular synthesis of the sugar “fucose” and hence, in antibody-producing cells, its addition to the N-linked carbohydrate part of the antibody. The absence of fucose is known to greatly enhance ADCC. The GlymaxX® technology is based on the stable introduction of a gene for an enzyme which blocks the producer cells’ fucose biosynthesis pathway. As a unique feature, differentiating it from other approaches, GlymaxX® can be applied to both novel or already existing antibody producer cell lines, and entire antibody expression and discovery platforms, without negatively affecting their productivity or other product characteristics.Furthermore, a single GlymaxX® cell line can be flexibly used to produce differently fucosylated products, depending on the upstream process: In fucose-free medium the antibody is quantitatively afucosylated. The same GlymaxX® cell line grown in fucose-containing medium however, uses the provided fucose and produces fully fucosylated antibody. Thus, a GlymaxX® cell line can by employed to produce different products: For instance ADCC-enhanced GlymaxX® antibodies or wildtype-like, fully fucosylated mAbs, for a parallel Antibody-Drug-Conjugate (ADC) project.Finally, GlymaxX® has been used by biosimilar-developing companies to adjust a specific content of fucose in order to match the originators glycoprofile. Overall, GlymaxX® is simple, rapid, potent, and universally applicable to different CHO hosts and all other eukaryotic cell species.ProBioGen offers its GlymaxX® technology royalty-free and non-exclusively as a service or as an individual license.2019 Asia-pacific pharma IP Leader Summit: http://en.zenseegroup.com/p/404716/ will be held in Beijing  on November 14-15, and will attract more than 500 industry experts from domestic and foreign pharmaceutical companies, biotechnology companies, governments, associations, law firms, intellectual property agents and other companies to attend.Official registration and consultation channels:Contact:AnnPhone: 021-65650305Email:Marketing@zenseegroup.comhttp://www.zenseegroup.com/forms/view/22113/

About Us
Contact Us
Zensee_Daystar online